Kaplan–Meier analyses further confirmed that DLBCL patients with elevated CXCR5 and LAG‐3 expression exhibited significantly lower post‐treatment 5‐year PFS and OS compared to those with lower expression levels. Here, LAG3 is linked to diffuse large B-cell lymphoma.